Saltikva® in Patients diagnosed with Stage 4 Metastatic Pancreatic Cancer
Saltikva is currently recruiting patients in its Phase 2 study in patients diagnosed with Stage 4, metastasized pancreatic cancer. Top line, interim results of the study are available. This program has been granted Orphan Drug and FastTrack designations by the US FDA. Contact us for more information on this clinical study.
Salktikva® in other solid tumors
Salspera is evaluating the study of Saltikva in other terminal, solid tumor cancers. These programs have completed IND-enabling studies and are slated to enter the clinical stage.
New therapeutic programs
Salspera has developed multiple new constructs with different capabilities, expressing various immuno-modulating proteins applicable for a diverse set of solid tumor cancers. These programs are in IND-enabling stages. Contact us at email@example.com for more information on our early stage programs.